Niagen Bioscience, Inc. (NAGE) AI Stock Analysis

Niagen Bioscience, Inc. operates as a bioscience company developing healthy aging products across three segments: Consumer products, Ingredients, and Pharmaceutical Segments. It provides finished dietary supplement products directly to consumers and distributors, including nicotinamide adenine dinucleotide (NAD+), a coenzyme that regulates cellular metabolism. The company commercializes proprietary ingredient technologies such as food-grade and pharmaceutical-grade Niagen, and supplies NAD+ precursor nicotinamide riboside as its flagship ingredient. Niagen Bioscience distributes TRU NIAGEN products direct to consumers via TRUNIAGEN.com, Amazon, other internet marketplaces, specialty retailers, and authorized healthcare practitioner resellers. Formerly known as ChromaDex Corporation, it rebranded in March 2025.

Revenue expanded at a 5-year CAGR of 16.9% from FY2020 through FY2025, rising from $67.4M in FY2021 to $129.4M in FY2025. Gross margin expanded from 61.5% in FY2021 to 64.3% in FY2025. Operating margin turned positive at 7.8% in FY2024 and reached 11.0% in FY2025, driving net income to $17.4M compared to a net loss of -$27.1M in FY2021. For the trailing twelve months, revenue was $129.1M with a net profit margin of 12.4% and an operating margin of 2.4%. However, in the latest quarter ended June 30, 2026, quarterly revenue growth fell 4.3% year-over-year and quarterly earnings growth declined 75.0%.

As of June 30, 2026, Niagen Bioscience held $66.7M in cash and short-term investments against $2.3M in total debt, resulting in net cash of $64.4M. Shareholders' equity stood at $82.5M alongside total assets of $106.6M. The company has a current ratio of 6.50 and a debt-to-equity ratio of 0.03. Operating cash flow reached $13.4M and free cash flow was $13.1M in FY2025. In that fiscal year, capital expenditures were $292,000 and share buybacks totaled $251,000, while its share count grew 20.8% over five years.

At a last close of $2.49, Niagen Bioscience trades at a trailing P/E of 13.1x, below the 18.6x median of its US-listed Consumer Defensive peers. Its forward P/E of 21.5x is higher than the peer median of 14.3x. The stock carries an enterprise value to EBITDA ratio of 16.9x versus the peer median of 11.7x, and a price-to-sales multiple of 1.5x compared to the peer median of 0.7x. Over the past year, shares fell 66.4%, while the SPY S&P 500 benchmark gained 16.8%. Over five years, the stock dropped 60.8% compared to an 83.0% gain for the S&P 500.

Consensus ratings show 6 Strong Buy recommendations, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $12.08, representing a 385.3% premium over the last close of $2.49. For the fiscal year ending December 31, 2026, analysts estimate revenue of $133.2M and EPS of $0.00, reflecting an estimated EPS decline of 100.0%. For the next fiscal year, consensus estimates revenue of $154.7M and an EPS of -$0.06. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Niagen Bioscience, Inc. (NAGE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NAGE income statement, NAGE balance sheet, NAGE key metrics, NAGE analyst forecast, NAGE chart. See the NAGE stock overview for the latest quote and news.